Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • From JHM
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • From JHM
  • Industry Content
    • Patient Monitoring with Tech

Initiation of Medications for AUD Prior to Discharge Leads to Lower Rates of Return to Hospital

linical question: How does the initiation of medications for alcohol use disorder (AUD) at discharge affect 30-day post-discharge outcomes?

Background: AUD is highly prevalent (affecting approximately 29 million adults) and leads to a high rate of health care utilization. Despite guideline recommendations, a majority of U.S. adults with AUD do not receive treatment with medications for AUD (MAUD). Hospitalizations offer a possible opportunity to encourage patients with AUD to engage in treatment with MAUD.

Study design: Retrospective cohort study

Setting: U.S. hospitals admitting Medicare beneficiaries in 2016

Synopsis: 6,794 patients enrolled in Medicare who were hospitalized for AUD in U.S. hospitals in 2016 encompassing 9,834 alcohol-related hospitalizations were included.  The primary outcome was a composite of 30-day all-cause mortality or return to hospital. The exposure of interest was MAUD at discharge, which included pharmacy claims for oral naltrexone, acamprosate, or disulfiram that were filled between the day before discharge and two days after discharge. 192 hospitalizations (2.0%) resulted in MAUD initiation on discharge. 30-day all-cause mortality or return to the hospital occurred in 4,843 hospitalizations (49.3%) of which 49 (25.5%) involved MAUD on discharge and 4,794 (49.7%) did not.  MAUD at discharge was associated with a 42% relative risk reduction (Incidence Rate Ratio, 0.58 [95% CI, 0.45 to 0.76]) and 18% absolute risk reduction (95% CI, −0.26 to −0.11) in 30-day all-cause mortality or return to hospital. Limitations of this study include unmeasured confounding as a byproduct of the observational study design, an inability to account for long-acting naltrexone injections administered prior to discharge, and an inability to account for non-pharmacologic interventions.

Bottom line: Initiation of naltrexone, acamprosate, or disulfiram prior to discharge or within two days of discharge leads to lower rates of 30-day post-discharge hospital return (emergency department visits and readmissions).

Citation: Bernstein EY, Baggett TP, et al. outcomes after initiation of medications for alcohol use disorder at hospital discharge. JAMA Netw Open. 2024;7(3):e243387. doi:10.1001/jamanetworkopen.2024.3387

Dr. Larson

Dr. Larson

Dr. Larson is a hospitalist in the division of hospital medicine at NYU Langone Tisch Hospital and a clinical assistant professor of medicine at the NYU Grossman School of Medicine, both in New York.

  • Initiation of Medications for AUD Prior to Discharge Leads to Lower Rates of Return to Hospital

    December 2, 2024

  • A Stepwise Approach to Inpatient Management of Hypertension

    December 2, 2024

  • Defining and Measuring Those Administrative Pressures We All Feel

    December 2, 2024

  • Expanded Care Roles for AI and Lots More: Seasoned Hospitalists Share Top Changes to the Specialty

    December 2, 2024

  • To Preround or Not?

    December 2, 2024

  • Part II From Abroad to Bedside: IMGs in the U.S. Healthcare System

    December 2, 2024

  • Interpretation of Serum Ammonia Level

    December 2, 2024

  • SIG Spotlight: Palliative Care

    December 2, 2024

  • Chapter Spotlight: Long Island

    December 2, 2024

  • When Should I Transfuse My Adult Hospitalized Patient Who Has Anemia?

    December 2, 2024

1 … 30 31 32 33 34 … 984
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences